Foghorn Therapeutics (NASDAQ:FHTX) Price Target Cut to $20.00

Foghorn Therapeutics (NASDAQ:FHTX – Get Rating) had its price objective decreased by research analysts at HC Wainwright from $25.00 to $20.00 in a research report issued on Tuesday, The Fly reports. HC Wainwright’s target price would indicate a potential upside of 268.32% from the company’s previous close. Several other analysts have also recently weighed in […]

Related Keywords

United States ,America , ,Victory Capital Management Inc ,Foghorn Therapeutics Inc ,Alphabet Inc ,Goldman Sachs Group Inc ,Foghorn Therapeutics ,Get Rating ,Therapeutics Stock Down ,Capital Management ,Sachs Group ,State Street Corp ,Street Corp ,Therapeutics Inc ,Gene Traffic Control ,Foghorn Therapeutics Daily ,Nasdaq Fhtx ,Fhtx ,Medical ,Lower Price Target ,Hc Wainwright ,